Skip to search formSkip to main contentSkip to account menu

BRL 49653

Known as: BRL-49653, BRL49653 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (2)

AvandiaRosiglitazone maleate

Broader (1)

rosiglitazone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
JTP‐426467 acts as a selective antagonist for peroxisome proliferator‐activated receptor γin vitro and in vivo
Aim:  JTP‐426467 was identified as a result of screening in search of selective antagonist for peroxisome proliferator‐activated… 
2005
2005
Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1.
Lung carcinoma often occurs in patients with chronic lung disease such as tobacco-related emphysema and asbestos-related… 
Highly Cited
2001
Highly Cited
2001
Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways.
The peroxisome proliferator-activated receptors (PPARs) are transcription factors involved in fatty acid metabolism and energy… 
2001
2001
Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells.
Cyclooxygenase-2 (COX-2) expression is up-regulated in colorectal cancer tissue. Peroxisome proliferator-activated receptors… 
2001
2001
Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway.
To elucidate the direct effect of rosiglitazone (RSG), a new thiazolidinedione antihyperglycemic agent, on pancreatic insulin… 
Highly Cited
2001
Highly Cited
2001
Automated high-performance liquid chromatography method for the determination of rosiglitazone in human plasma.
Highly Cited
1999
Highly Cited
1999
The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.
Human obesity is associated with insulin resistance, hyperinsulinemia, and a predisposition to hypertension and vascular disease… 
1999
1999
Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation.
Increased plasma triglyceride concentrations are often observed in metabolic disorders predisposing to coronary heart disease… 
Highly Cited
1997
Highly Cited
1997
Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y
1 The thiazolidinedione BRL 49653 (rosiglitazone) induces hyperphagia and weight gain in obese, insulin‐resistant fatty Zucker… 
1995
1995
Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb.
Hindlimbs of mature age obese fa/fa Zucker rats were perfused and found to be markedly insulin-resistant when compared to the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)